ALK-Abelló and Menarini Sign Agreement

ALK-Abelló A/S and Menarini Group have signed an agreement for co-promotion, distribution and licensing of ALK-Abelló's tablet-based vaccine against grass pollen allergy, GRAZAX, and two coming tablet products in development for the European market.

The agreement provides broad European availability of the tablet-based vaccines in areas where ALK-Abelló has a limited presence.

ALK-Abelló and Menarini will co-promote GRAZAX in the UK, Belgium, Ireland and Luxembourg. Menarini receives exclusive rights to promote, sell and distribute GRAZAX in the following EU countries: Greece, Portugal, Poland, Czech Republic, Hungary, Slovenia, Slovakia, Latvia, Lithuania, Estonia, Cyprus and Malta. Menarini receives exclusive licensing rights in the non-EU countries Russia, Turkey, Romania, Croatia, Serbia, Bulgaria, Ukraine, Kazakhstan and Belarus. In these countries, Menarini will also handle the national approval procedures.

Under the agreement, Menarini will purchase the products from ALK-Abelló for sales in all the above-mentioned markets. In markets where GRAZAX is co-promoted, the companies will also share the profit proportional to their marketing efforts.

For further information please contact:

Jens Bager,

President and CEO

Tel: +45 45 74 74 45

Email: mailbox@alk-abello.com

Or visit: www.alk-abello.com